​INDIvidualised drug therapy: Focus on carboxylesterase1 (CES1), research manager, senior Researcher Pia Jeppesen.

Aim: To examine the relationship between individual variations in CES1 genotype, and beneficial and harmful effects of Methylphenidate (MPH) treatment in ADHD, and develop guidelines for treatment based on genotype.

Design: A prospective, longitudinal, observational study. 
A clinical cohort of 207 children, recently diagnosed with ADHD, were assessed for CES1 genotype, and monitored weekly under standardized conditions, for effects, side effects, functioning and doses, during the first 12 weeks of MPH treatment.

Responsible editor